항비만약 시장 규모, 점유율, 성장 분석 : 약 유형별, 작용별, 투여별, 지역별 - 산업 예측(2025-2032년)
Anti Obesity Drugs Market Size, Share, Growth Analysis, By Drug Type, By Action, By Administration, By Region - Industry Forecast 2025-2032
상품코드:1630628
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 165 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 항비만약 시장 규모는 2023년에 37억 달러로 평가되며, 2024년 46억 7,000만 달러에서 2032년에는 302억 6,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 26.3%로 성장할 전망입니다.
세계비만연맹(World Obesity Federation)은 비만 관련 비용이 50% 이상 급증하여 2025년 말까지 약 1조 2,000억 달러에 달할 것으로 예상하고 있습니다. 이러한 급격한 증가는 제약업계가 비만 대책에 효과적인 솔루션 개발에 집중하고 있음을 강조하고 있습니다. 환자 수가 증가하고 치료율이 낮게 유지되고 있으므로 신규 시장 진출기업에게는 큰 기회가 있습니다. 비만 인식 개선 노력과 지원적인 비용 상환 정책의 확립은 제품 수요를 촉진할 가능성이 높으며, COVID-19 팬데믹은 역설적으로 비만과 관련된 건강 위험 증가로 인해 보건 당국이 관리 지침을 발표함에 따라 승인된 항비만제의 판매를 촉진하고 있습니다. 역설적으로 승인된 항비만약의 판매를 촉진하고 있습니다. 또한 봉쇄로 인해 앉아서 생활하는 시간이 늘어나면서 비만 치료에 대한 수요가 증가하여 시장 성장을 가속할 수 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
특허 분석
규제 분석
항비만약 시장 규모 : 약 유형별
시장 개요
처방약
시판약
항비만약 시장 규모 : 작용별
시장 개요
중추 작용형 항비만약
말초 작용형 항비만약
항비만약 시장 규모 : 투여별
시장 개요
경구투여
피하 투여
항비만약 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
항비만약 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Novo Nordisk A/S(Denmark)
Eli Lilly and Company(USA)
Roche Holding AG(Switzerland)
Pfizer Inc.(USA)
Currax Pharmaceuticals LLC(USA)
Boehringer Ingelheim International GmbH(Germany)
Amgen Inc.(USA)
AstraZeneca PLC(UK/Sweden)
GlaxoSmithKline plc(UK)
Sanofi S.A.(France)
Rhythm Pharmaceuticals, Inc.(USA)
Gelesis Holdings, Inc.(USA)
Merck & Co., Inc.(USA)
Takeda Pharmaceutical Company Limited(Japan)
Eisai Co., Ltd.(Japan)
Orexigen Therapeutics, Inc.(USA)
Zafgen Inc.(USA)(Ceased operations)
VIVUS LLC(USA)(Acquired by Currax Pharmaceuticals)
Cheplapharm Arzneimittel GmbH(Germany)
KVK Tech Inc.(USA)
결론과 권장사항
KSA
영문 목차
영문목차
Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).
The World Obesity Federation forecasts that obesity-related costs will surge by over 50%, reaching approximately $1.2 trillion by the end of 2025. This escalation emphasizes the pharmaceutical industry's focus on developing effective solutions to combat obesity. As the patient population grows and treatment rates remain low, there are significant opportunities for new entrants in the market. Initiatives aimed at educating the public about obesity and the establishment of supportive reimbursement policies are likely to drive product demand. The COVID-19 pandemic has paradoxically boosted sales of approved anti-obesity medications, as heightened health risks associated with obesity have prompted health organizations to issue management guidelines. Furthermore, increased sedentary behavior due to lockdowns has intensified the need for obesity treatments, potentially enhancing market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Obesity Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Anti Obesity Drugs Market Segmental Analysis
Global Anti Obesity Drugs Market is segmented by Drug Type, Action, Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Prescription Drug and Over the Counter Drugs. Based on Action, the market is segmented into Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs. Based on Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Anti Obesity Drugs Market
The global anti-obesity drugs market is significantly driven by escalating concerns regarding effective obesity management, propelled by the alarming rise in obesity rates among populations worldwide. Currently, the World Obesity Federation reports staggering figures of approximately 650 million adults and 120 million children grappling with obesity, leading to an annual expenditure of around US$ 2 trillion for obesity-related healthcare. Furthermore, the Centers for Disease Control and Prevention (CDC) indicates that 42.5% of adults in the United States are classified as obese. This escalating awareness, particularly in emerging economies, about the necessity of timely weight management is anticipated to further fuel the demand for anti-obesity medications in the market over the coming years.
Restraints in the Global Anti Obesity Drugs Market
The Global Anti-Obesity Drugs market faces significant restraints, despite the increasing prevalence of obesity worldwide. Treatment rates remain low, primarily due to a lack of awareness regarding weight management and widespread misconceptions about obesity. Our research indicates that only 2% of individuals with obesity receive prescription medication for their condition, reflecting low acceptance of these drugs, which hampers market growth. Additionally, the market is constrained by the limited number of key companies focused on developing obesity treatments and the adverse effects associated with these medications, further impeding broader adoption and expansion of anti-obesity solutions.
Market Trends of the Global Anti Obesity Drugs Market
The Global Anti-Obesity Drugs market is witnessing a significant trend towards the development of dual-action therapeutic compounds aimed at simultaneously addressing both Type 2 diabetes mellitus and obesity. This burgeoning focus is driven by the alarming increase in obesity rates and the corresponding prevalence of Type 2 diabetes, prompting pharmaceutical companies and researchers to innovate and create effective medications that tackle these interrelated health issues. With unhealthy dietary habits, sedentary lifestyles, and a growing obese population persisting as key challenges, the market is poised for substantial growth in the coming years, presenting lucrative opportunities for stakeholders in the healthcare sector.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Patent Analysis
Regulatory Analysis
Global Anti Obesity Drugs Market Size by Drug Type & CAGR (2025-2032)
Market Overview
Prescription Drug
Over the Counter Drugs
Global Anti Obesity Drugs Market Size by Action & CAGR (2025-2032)
Market Overview
Centrally Acting Anti-Obesity Drugs
Peripherally Acting Anti-Obesity Drugs
Global Anti Obesity Drugs Market Size by Administration & CAGR (2025-2032)
Market Overview
Oral Route
Subcutaneous Route
Global Anti Obesity Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti Obesity Drugs Market Size & CAGR (2025-2032)
North America (Drug Type, Action, Administration, Distribution Channel)
US
Canada
Europe (Drug Type, Action, Administration, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Drug Type, Action, Administration, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Drug Type, Action, Administration, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Drug Type, Action, Administration, Distribution Channel)
GCC Countries
South Africa
Rest of Middle East & Africa
Competitive Intelligence
Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
Company Details
Product Portfolio Analysis
Company's Segmental Share Analysis
Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
Novo Nordisk A/S (Denmark)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Eli Lilly and Company (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Roche Holding AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Pfizer Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Currax Pharmaceuticals LLC (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Boehringer Ingelheim International GmbH (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Amgen Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
AstraZeneca PLC (UK/Sweden)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
GlaxoSmithKline plc (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Sanofi S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Rhythm Pharmaceuticals, Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Gelesis Holdings, Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Merck & Co., Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Takeda Pharmaceutical Company Limited (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Eisai Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Orexigen Therapeutics, Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Zafgen Inc. (USA) (Ceased operations)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
VIVUS LLC (USA) (Acquired by Currax Pharmaceuticals)
